[The clinico-pharmacological characteristics of anteovin]. / Kliniko-farmakologicheskaia kharakteristika anteovina.

The clinical and laboratory studies carried out on 160 women showed a high contraceptive effect and good tolerance of anteovine. The contraceptive effect of the biphasic drug is determined by its antiovulatory action concurrent with inhibition of the basal periovulatory secretion of gonadotropins and secretion of sex hormones.

PIP: The results of evaluation of the contraceptive activity of the biphasic oral contraceptive anteovin are presented. 1 package of anteovin consists of 11 white tablets containing 0.05 mg of ethinyl estradiol and 0.05 mg of levonorgestrel and 10 pink tablets of 0.05 mg of ethinyl estradiol and 0.125 mg of levonorgestrel. Anteovin was tested according to the conventional 21-day regimen from day 5 of the cycle for 21 days, followed by 1 7-day rest period. Duration of anteovin administration ranged from 1 to 12 cycles. Anteovin was given to 160 women (aged 17 to 40 years old) who had a history of 618 pregnancies (182 ended by term delivery and 436 ended by induced abortion). During anteovin administration none of the women became pregnant. Side effects of anteovin included mild nausea during first several days in 12 women, breast tenderness in 4, and menstruation disorders in 8. The mechanism of contraceptive effect of anteovin was associated with ovulation inhibition. The changes in the basal temperature had a monophasic characteristic. Colpocytological examination showed decrease in the karyopyknotic and eosinophilic indices to 4-30%. All estrogen fractions (estrone, estradiol and estriol) in the urine showed statistically significant decrease on day 14-16 of the cycle (to 15.8 mcg/day, compared with 41.9 mcg/day in controls). The level of pregnanediol in the urine showed a decrease on day 20-23 of the cycle (0.66 mg/day, compared with 2.98 mg/day in controls). After 6 months of anteovin administration, there was a decrease in the basal and periovulation secretion of follicle-stimulating hormone, luteinizing hormone, and estradiol.

[Clinico-laboratory research on the pharmacodynamic characteristics of Rigevidon]. / Kliniko-laboratornoe issledovanie osobennostei farmakodinamiki rigevidona.

A contraceptive effect of Rigevidon depends on the drug influence on cyclic secretion of gonadotropic hormones. Rigevidon fails to exert a significant effect on prolactin secretion. The drug withdrawal results in a comparatively rapid restoration (within the first three months) of the generative function.

PIP: The effect of the new combined oral contraceptive agent Rigevidon on the hypothalamo-hypophyseal-ovarian system was studied in 50 women (age not specified). Rigevidon was given for 21 days with subsequent 7-day interval. Duration of administration was 10-12 cycles. Functional state of the ovaries and gonadotropic function of the pituitary gland was evaluated by measuring the blood levels of estradiol, progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). During Rigevidon administration in doses producing the contraceptive effect, all women showed the monophasic type of basal temperature. FSH levels on days 7-9 and 20-23 of cycle 3, 6 and 10-12 did not differ significantly from those in controls; there was a 2.8 times decrease FSH levels on days 14-16 of cycle 3 and a 3.8 times decrease on days 14-16 of cycle 10-12. Marked decrease in LH levels was observed on days 14-16 of cycle (5 times) and during the 6th cycle (9.2 times). Significant decrease in estradiol levels was recorded on days 7-9 and 14-16 of cycle 3,6 and 10-12. Progesterone levels were decreased significantly on days 7-9 and 20-23 of cycle 3, 6 and 10-12; significant decrease in progesterone levels on days 14-16 was observed only during cycle 3. Prolonged administration of Rigevidon (10-12 cycles) produced no changes in prolactin secretion. After cessation of Rigevidon administration, the LH and estradiol levels were decreased only on days 14-16 of cycle 1. The test with LH releasing hormone (100 mc) on days 12-14 after Rigevidon cessation showed normal sensitivity of the pituitary gland to hypothalamic stimulation. The results of this study indicate that the contraceptive effect of Rigevidon is associated with inhibition of ovulation and cyclic secretion of FSH and LH.

[Sensitivity of the pituitary gland to LH-FSH releasing hormone in women after discontinuation of ovidon, an estrogen-progesterone contraceptive agent]. / Chuvstvitel'nost' gipofiza k LG-FSG-rilizing-gormonu u zhenshchin posle otmeny éstrogen-progestagennogo kontratsepnivnogo preparata ovidona.

PIP: Serum luteinizing hormone and follicle stimulating hormone patterns in response to intravenous administration of 100 mcg luteinizing hormone-releasing hormone (LH-RH) during the follicular phase of the cycle were examined in 8 women upon the discontinuation of a combined contraceptive, Ovidon, and in 11 untreated women. The duration of treatment was 9-12 months. Pituitary response to LH-RH was found to be diminished significantly in the treated patients. (author's)^ieng